For the first time, major health organizations worldwide are uniting to demand that the World Health Assembly pass an official resolution on steatotic liver disease, commonly known as fatty liver disease. This coordinated push represents a significant shift in how the global health community views a condition that affects hundreds of millions of people but has been largely overlooked by international health policy .

What Is Steatotic Liver Disease and Why Does It Matter?

Steatotic liver disease, also called metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH), occurs when fat accumulates in liver cells. Unlike fatty liver disease caused primarily by alcohol consumption, MASLD develops in people with metabolic problems like obesity, diabetes, and insulin resistance. The condition can progress silently, potentially leading to liver fibrosis, cirrhosis, and liver cancer if left untreated .

The burden of this disease extends far beyond individual patients. Steatotic liver disease carries a substantial human and economic cost globally, yet it remains conspicuously absent from World Health Organization normative guidance, action plans, and strategies. This gap in international health policy has prompted patient organizations, national health agencies, and international medical societies to take action .

Who Is Behind This Global Push?

The position statement calling for a World Health Assembly resolution has been endorsed by an unprecedented coalition of organizations spanning multiple continents. This includes patient advocacy groups, national liver disease associations, diabetes organizations, cardiovascular health networks, and gastroenterological societies from countries including Canada, Australia, Thailand, Taiwan, Egypt, Brazil, Spain, and many others .

The breadth of this endorsement underscores how steatotic liver disease intersects with multiple health conditions. Organizations focused on diabetes, obesity, cardiovascular disease, and general internal medicine have all signed on, recognizing that their patient populations are significantly affected by liver health issues .

Why Is WHO Recognition So Important?

A World Health Assembly resolution would represent official global acknowledgment of steatotic liver disease as a public health priority. This recognition typically leads to several concrete outcomes:

• Policy Development: WHO member countries would be encouraged to develop national action plans and strategies specifically addressing steatotic liver disease prevention and management.
• Resource Allocation: Official recognition often triggers funding for research, surveillance systems, and public health interventions focused on the disease.
• Clinical Guidelines: WHO normative guidance would provide evidence-based recommendations for screening, diagnosis, and treatment that countries could implement in their healthcare systems.
• Public Awareness: International attention increases media coverage and public education campaigns, helping people understand their risk and seek appropriate care.

What Would a Global Action Agenda Look Like?

Experts and organizations involved in this effort have already outlined priorities for addressing steatotic liver disease on a global scale. These recommendations focus on practical, achievable interventions that countries can implement regardless of their economic resources. The goal is to create a comprehensive approach that combines prevention, early detection, and effective treatment strategies .

The timing of this push is significant. As obesity and type 2 diabetes rates continue to climb worldwide, steatotic liver disease is becoming increasingly common. Without coordinated global action, the disease is expected to become a leading cause of liver-related illness and death in coming decades .

How Can Countries Prepare for This Resolution?

Health policy experts have identified several key steps that countries should take to prepare for and implement a potential World Health Assembly resolution on steatotic liver disease:

• Assessment of Current Readiness: Countries should evaluate their existing capacity to screen for, diagnose, and manage steatotic liver disease, including availability of liver specialists, imaging technology, and laboratory testing for liver enzymes like ALT and AST.
• Integration with Existing Programs: Steatotic liver disease prevention and management should be incorporated into existing diabetes, obesity, and cardiovascular disease programs rather than treated as a separate health issue.
• Training and Education: Healthcare providers, particularly primary care physicians, need education about recognizing risk factors and identifying patients who should be screened for liver disease.
• Public Health Campaigns: Countries should develop awareness initiatives explaining the connection between metabolic health, lifestyle factors, and liver disease risk.

The position statement emphasizes that steatotic liver disease represents a "missing piece" in the global response to noncommunicable diseases like diabetes and obesity. By securing a World Health Assembly resolution, health leaders hope to ensure that liver health receives the attention and resources it deserves in international public health efforts .

This coordinated global effort signals a turning point in how the health community views fatty liver disease. Rather than treating it as a secondary concern for specialists, the push for WHO recognition acknowledges that steatotic liver disease is a major public health challenge requiring coordinated international action, investment in research and prevention, and integration into broader metabolic health strategies.